Implicity Secures FDA Clearance for Innovative Heart Failure Prediction Algorithm
Implicity, a leading provider of remote patient monitoring and cardiac data management solutions, has obtained…
What is CAR-T cell therapy?
CAR-T cell therapy, short for Chimeric Antigen Receptor T-cell therapy, is a revolutionary form ofimmunotherapy that has gained significant attention in recent years for its remarkable success intreating certain types of cancer, particularly blood cancers. This cutting-edge treatment involvesharnessing the power of the patient’s immune system to target and destroy cancer cells, offeringnew hope for…
Crucible Therapeutics, a spinout of the University of Sheffield in England, has secured £5million (approximately $6.1 million) in funding to advance its development of genetherapies
Gene therapies will be targeting neurodegenerative disorders associated with C9orf72gene mutations. The financing comes from investment firm Northern Gritstone and Europeanstartup studio Argobio Studio. These funds will support preclinical development andmanufacturing efforts aimed at preparing Crucible Therapeutics for its initial clinical trial. Thecompany’s focus is on addressing conditions such as motor neuron disease (MND), amyotrophiclateral…
Navigate BioPharma, a subsidiary of Novartis, has recently announced a strategic collaboration with Becton Dickinson (BD)
Collaboration aimed at advancing the development and commercialization of companion diagnostics and clinical decision-making tools utilizing flow cytometry technology. This partnership represents a significant step in the field of precisionmedicine and holds the potential to enhance the efficiency and accuracy of patient treatmentmatching.Through this collaborative effort, BD and Navigate BioPharma aim to offer comprehensivesolutions for…
AstraZeneca and Daiichi’s breast cancer drug Shows Promise in Phase III BreastCancer Trial
AstraZeneca’s Dato-DXd, an antibody drug conjugate, has shown promising results in a Phase IIIbreast cancer trial, known as TROPION-Breast01, conducted to assess its effectiveness inpatients with advanced HR-positive, HER2-low or -negative breast cancer. The trial revealed asignificant and clinically meaningful improvement in progression-free survival when comparedto chemotherapy chosen by investigators. AstraZeneca intends to share these…
Implicity Secures FDA Clearance for Innovative Heart Failure Prediction Algorithm
Implicity, a leading provider of remote patient monitoring and cardiac data management solutions, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative algorithm, SignalHF*. This groundbreaking algorithm, integrated into Implicity’s remote monitoring solution, is designed to assess the risk of future heart failure events based on comprehensive patient data….
Tezspire® Reveals Promise for COPD Patients: New Findings Unveiled at ATS 2024
Amgen and AstraZeneca disclosed the outcomes of the Phase 2a COURSE trial assessing Tezspire® (tezepelumab-ekko) in individuals with moderate to very severe chronic obstructive pulmonary disease (COPD), irrespective of their baseline blood eosinophil counts (BEC), emphysema, chronic bronchitis, or smoking history. Although the primary results did not achieve statistical significance, with a 17% numerical reduction…
Exploring Innovations in Colorectal Cancer Screening: Liquid Biopsy and Beyond
Colorectal cancer (CRC) remains a significant global health challenge due to its high incidence and mortality rates. Despite advancements in treatment, identifying patients who could benefit from specific therapies remains challenging. Traditional tissue biopsies have limitations such as spatial and temporal heterogeneity. Liquid biopsy (LB), particularly circulating tumor DNA (ctDNA) analysis, emerges as a promising…
WHO Revises Catalog of Drug-Resistant Bacteria Posing Greatest Human Health Risks
The World Health Organization (WHO) has unveiled its updated Bacterial Priority Pathogens List (BPPL) for 2024, spotlighting 15 families of antibiotic-resistant bacteria classified into critical, high, and medium priority categories. This initiative aims to steer research and development efforts towards combating antimicrobial resistance (AMR), a global health crisis exacerbated by the misuse of antibiotics. Critical…
FDA Grants Approval for IMDELLTRA™ (Tarlatamab-dlle): First T-cell Engager Therapy for Extensive-Stage Small Cell Lung Cancer
Amgen’s IMDELLTRA™ (tarlatamab-dlle) has gained FDA approval for treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) post platinum-based chemotherapy progression. This milestone reflects a significant advancement, offering hope to a patient population with limited treatment options. The approval is based on compelling data from the Phase 2 DeLLphi-301 trial, showcasing IMDELLTRA’s efficacy in…
Merck to Unveil Latest Findings at 2024 ASCO Annual Meeting Showcasing Progress in Innovative Oncology Treatments Across Extensive Portfolio and Varied Pipeline
Merck, also known as MSD outside the United States and Canada, is set to unveil a wealth of data at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, spanning various oncology medicines and pipeline candidates targeting over 25 types of cancer. These presentations highlight Merck’s ongoing commitment to advancing cancer research…
Diasorin Secures FDA 510(k) Clearance for Enhanced Respiratory Panel
Diasorin recently announced that the US Food and Drug Administration has granted 510(k) marketing clearance for their updated molecular respiratory panel, now including SARS-CoV-2 detection. The NxTag Respiratory Pathogen Panel v2, based in Saluggia, Italy, utilizes multiplex PCR to identify 19 viral and two bacterial targets in nasopharyngeal swab samples from patients displaying respiratory symptoms….
Seegene and Springer Nature Forge Strategic Partnership
Seegene , a leading South Korean PCR molecular diagnostics company, has entered a strategic alliance with Springer Nature, publisher of the prestigious journal, Nature. Aligned in their mission to advance scientific discovery and combat diseases, this alliance aims to accelerate PCR diagnostic testing across various disease areas. The collaboration leverages the expertise of both parties…
Radiation oncology in the era of Precision Medicine
Radiation therapy utilizes high doses of ionizing or particulate radiation to kill cancer cells. It is an integral component of multimodality cancer care. However, the challenge lies in delivering it precisely to the target while sparing surrounding healthy tissues. Technological advancements have revolutionised radiation therapy planning and delivery leaps and bounds. Especially incorporation of axial…
U.S. FDA Grants Approval to Bristol Myers Squibb’s Breyanzi CAR T Cell Therapy for Relapsed or Refractory Follicular Lymphoma
Bristol Myers Squibb has received accelerated approval from the U.S. Food and Drug Administration (FDA) for Breyanzi® (lisocabtagene maraleucel; liso-cel), a CAR T cell therapy targeting CD19, to treat adult patients with relapsed or refractory follicular lymphoma (FL) who have undergone two or more prior lines of systemic therapy. This approval, based on response rate…
